- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06472544
Trauma-Informed Intervention for Rheumatoid Arthritis on Blackfeet Nation
Trauma-informed Intervention for Rheumatoid Arthritis on Blackfeet Nation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence rate of rheumatoid arthritis (RA) in Blackfeet Nation members is among the highest in North America. With our current NARCH funding, we have found that cultural connectiveness in members of the Blackfeet Nation ameliorated the pro-inflammatory effects associated with high exposure to adverse childhood experiences (ACES). This raises the question of whether improving cultural connectedness might be an effective, trauma-informed approach to improve function, outcome, and/or a sense of well-being in individuals with rheumatic diseases such as RA. The plausibility of taking this approach is grounded on the high exposure rates to ACEs in individuals living on and near the Blackfeet Reservation and the strong association between ACEs and systemic inflammation. Thus, we will test the hypothesis that a trauma-informed intervention aimed to improve cultural connectiveness will improve subjective and objective features of RA in individuals living on or near the Blackfeet Nation Reservation. This research project will serve the overall goal of the NARCH grant by: (1) building on past NARCH research to better understand physical and mental health of the Blackfeet Nation; (2) building capacity for health research at BCC-CCM through engagement and training of BCC students, driving scholarly productivity of BCC faculty, and building new inter-institutional collaborations; and (3) generate compelling results to address health concerns for the Blackfeet Nation. We propose 2 aims that can be accomplished over the time frame of this application:
Specific Aim 1: We will test the effects of a 2-week intervention designed to connect individuals with RA more strongly to Blackfeet language, cultures, ceremonies, and land. This pilot intervention of limited size will consist of assessing the clinical symptoms of RA, ACES scores, and biomarkers of inflammation before and immediately after the culturally grounded intervention. This pilot will inform a second, more encompassing intervention in aim 2. Specific Aim 2: We will test the hypothesis that a 2-week intervention to improve cultural connectedness in individuals with RA living on or near the Blackfeet Nation result in objective changes to pro-inflammatory markers, including markers associated with disease activity in RA. We believe developing an intervention which could reduce systemic inflammation could not only ameliorate symptoms of RA but possibly other inflammation-mediated diseases as well.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Betty Matthews
- Phone Number: 14068454583
- Email: b_mathews@bfcc.edu
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria: Diagnosis or self reporting of rheumatoid arthritis or use of rheumatoid arthritis medications.
Self reported Blackfeet heritage. -
Exclusion Criteria: Children under 18 years of age.
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Culturally Grounded Intervention
One week of meetings to describe Blackfeet history, culture, traditions, and cerimonies.
One additional week of visiting Blackfeet sacred sites.
|
Education to increase awareness of Blackfeet culture and connectedness to Blackfeet community
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rheumatoid Arthritis Disease Activity
Time Frame: Outcomes will be determined just before the intervention (day 1), just after intervention (day 14) and 6 months later.
|
Arthritis activity will be determined bu clinical assessments and self-reported symptom severity.
|
Outcomes will be determined just before the intervention (day 1), just after intervention (day 14) and 6 months later.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systemic Inflammation
Time Frame: Systemic inflammation determined immediately before intervention (day 1), immediately after end of intervention 9Day 14), and 6 months after intervention.
|
Systemic inflammation determined by assessing blood levels of inflammation biomarkers CRP, IL-6 and IL-17.
|
Systemic inflammation determined immediately before intervention (day 1), immediately after end of intervention 9Day 14), and 6 months after intervention.
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1674119
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
-
David Grant U.S. Air Force Medical CenterCompleted
Clinical Trials on Culturally Grounded Intervention
-
University of Colorado, DenverWashington State University; Missouri Breaks Industries Research, Inc.CompletedAlzheimer DiseaseUnited States
-
Clalit Health ServicesBen-Gurion University of the NegevUnknownPostpartum Depression
-
Cairo UniversityNot yet recruitingPatient-centered Care | Primary Health Care Providers | Culturally Responsive Care
-
University of Illinois at Urbana-ChampaignCompletedMental Health IssueUnited States
-
Butler HospitalNational Institute on Drug Abuse (NIDA)CompletedHIV Infections | Tobacco DependenceUnited States
-
Florida State UniversityUniversity of Minnesota; University of North Carolina; Northern Arizona University and other collaboratorsCompleted
-
Pakistan Institute of Living and LearningUniversity of Manchester; Dow University of Health Sciences; Abbasi Shaheed HospitalCompleted
-
University of HawaiiNational Kidney FoundationNot yet recruitingKidney Disease, ChronicUnited States
-
Koç UniversityCompletedPsychological Distress | Well-beingTurkey
-
Fox Chase Cancer CenterNational Cancer Institute (NCI); American Cancer Society, Inc.Completed